Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
about
Antibiotic strategies in the era of multidrug resistanceBeyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesBloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteriaNew Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsClinical management of infections caused by multidrug-resistant EnterobacteriaceaeRole of novel multidrug efflux pump involved in drug resistance in Klebsiella pneumoniaeRetrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae.Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae.Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensCarbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patientsComorbidities and disease severity as risk factors for carbapenem-resistant Klebsiella pneumoniae colonization: report of an experience in an internal medicine unit.Functional characterization of a novel outer membrane porin KpnO, regulated by PhoBR two-component system in Klebsiella pneumoniae NTUH-K2044.Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.Detection of blaIMP4 and blaNDM1 harboring Klebsiella pneumoniae isolates in a university hospital in MalaysiaImpact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimensKlebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsDosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Bloodstream infections in neutropenic cancer patients: A practical update.Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection modelSevere Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant Enterobacter cloacaeEvaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.Confronting carbapenemase-producing Klebsiella pneumoniae.Treatment of multidrug-resistant Gram-negative infections in children.Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.Antibiotic resistance in cancer patients.Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
P2860
Q26744091-3FB9E56F-F920-4BF4-A1B2-E50579E49CDDQ26747580-C75AF450-7D08-45E5-907A-575179871841Q26795565-977E8EF2-514D-4EEF-A1FD-8472D5D702CDQ26799580-2AE45D7D-AA54-4BC5-AAD1-101EF126ADC5Q28082546-FF079FF2-797B-4EC3-B19A-3A3249C00169Q28246841-DAB706A4-B4F5-4582-9F05-C1B259B20388Q28538740-0DD77671-FB79-42CB-8A2F-49C95DA61679Q33597689-DCF7DD7C-D180-450A-A42F-E1C71C9425CFQ33623060-80C60766-5D3D-4342-92F4-218B4C5158ECQ33798081-AC293748-E54F-40ED-85D0-B94D1B24DB69Q33816251-9E10A535-B4A8-4940-8720-367C680F5816Q34303970-E7955141-A051-4DF3-B373-B6701F47A29EQ34320945-9AA2489F-347A-4D05-9A6F-D6FBD61D0CADQ34327857-2B360E4F-BE64-41C6-B6FC-8A20CC2FC359Q34336456-2D37236A-D1DA-40AC-9EF7-578AE2B8654BQ34343968-7F50157E-DFF3-4114-9B98-6180ECBDA613Q34358548-F667699B-3529-4F99-AE8E-D0C09D17C6F5Q34437229-58B745C6-B402-409B-96CB-7E1121AB5FA3Q34916515-D055A6DA-9644-442F-B153-E0986B7F7C3EQ35170364-AD44AA4D-880C-4F51-9CE2-D765A6386E04Q35746258-3287EB80-87B1-408C-B778-952703AFCDCDQ35867414-56DB3108-AD88-4F73-A652-A4A1650E1123Q36150730-8D05AC2A-31FF-43C9-9FF2-A20A489C3ED4Q36361921-4EF299F8-9600-483A-A9F8-A7D096566D88Q36396195-D3BD1F55-C107-4D0B-A3FE-099C74498732Q36761826-6F9FE309-1A25-4624-BA73-BCCE79963898Q36913345-D26F3E62-D3A5-46F8-9AF9-1C78EC781A60Q37036574-38553B88-BAB7-454A-948D-54C26D1A9130Q37206036-E8C37800-AD0A-47EC-BAFD-1A0C2D1258E9Q37377897-E497A6E1-DC3A-4108-898E-DFAC26264C11Q37528489-A5A50C17-969B-4E2C-A90A-1F34950AC535Q37643655-DA006AF7-D561-4F52-9633-4759CA61431EQ38068604-13A11F1A-4A22-4A1D-9A90-FB9BA7F6BCD0Q38115356-A580CBA4-3AF1-4073-8668-9E2BE965F3F4Q38135903-35CC46B2-16A7-471D-8F11-6B95496B0FD3Q38185648-8008C2C8-082E-4C5F-9C28-ED95C82E97C5Q38199180-78E6E9FD-BE2A-407E-861C-760685FBAB85Q38212258-3AEEE54F-85D1-4CAF-BAA4-0376C138CFCEQ38216011-7A343897-9132-4252-928E-6381A99B8FB2Q38231648-836CD39C-B2B5-426E-BFF4-C7440C7484EF
P2860
Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Carbapenemase-producing Klebsi ...... der treating with carbapenems?
@en
Carbapenemase-producing Klebsiella pneumoniae:
@nl
type
label
Carbapenemase-producing Klebsi ...... der treating with carbapenems?
@en
Carbapenemase-producing Klebsiella pneumoniae:
@nl
prefLabel
Carbapenemase-producing Klebsi ...... der treating with carbapenems?
@en
Carbapenemase-producing Klebsiella pneumoniae:
@nl
P1476
Carbapenemase-producing Klebsi ...... der treating with carbapenems?
@en
P2093
A Markogiannakis
G L Daikos
P304
P356
10.1111/J.1469-0691.2011.03553.X
P577
2011-06-02T00:00:00Z